El-Halfawy Omar M, Valvano Miguel A
Centre for Human Immunology and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Centre for Human Immunology and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada Centre for Infection and Immunity, Queen's University Belfast, Belfast, United Kingdom
Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14.
"Heteroresistance" describes a phenomenon where subpopulations of seemingly isogenic bacteria exhibit a range of susceptibilities to a particular antibiotic. Unfortunately, a lack of standard methods to determine heteroresistance has led to inappropriate use of this term. Heteroresistance has been recognized since at least 1947 and occurs in Gram-positive and Gram-negative bacteria. Its clinical relevance may be considerable, since more resistant subpopulations may be selected during antimicrobial therapy. However, the use of nonstandard methods to define heteroresistance, which are costly and involve considerable labor and resources, precludes evaluating the clinical magnitude and severity of this phenomenon. We review the available literature on antibiotic heteroresistance and propose recommendations for definitions and determination criteria for heteroresistant bacteria. This will help in assessing the global clinical impact of heteroresistance and developing uniform guidelines for improved therapeutic outcomes.
“异质性耐药”描述了一种现象,即看似同基因的细菌亚群对特定抗生素表现出一系列敏感性。不幸的是,缺乏用于确定异质性耐药的标准方法导致了该术语的不当使用。异质性耐药至少自1947年以来就已被认识到,并且在革兰氏阳性菌和革兰氏阴性菌中均有发生。其临床相关性可能相当大,因为在抗菌治疗期间可能会选择出更具耐药性的亚群。然而,使用成本高昂且需要大量人力和资源的非标准方法来定义异质性耐药,妨碍了对这一现象的临床严重程度和影响的评估。我们回顾了关于抗生素异质性耐药的现有文献,并针对异质性耐药细菌的定义和判定标准提出建议。这将有助于评估异质性耐药的全球临床影响,并制定统一的指南以改善治疗效果。